FMC Corp Earnings Call Balances Risk And Recovery

FMC Corp ((FMC)) has held its Q2 earnings call. Read on for the main highlights of the call.

FMC Corp’s latest earnings call painted a mixed picture of cautious optimism. Management highlighted better‑than‑expected Q1 results, strong momentum in new technologies and key regulatory wins. Yet they openly acknowledged sharp near‑term profit compression, weak free cash flow and high leverage. The message was clear: H1 is the trough, and execution will determine the pace of recovery.

Q1 Revenue Beat Guidance Despite Year‑on‑Year Decline

FMC reported Q1 sales of $762 million, coming in $12 million above the guidance midpoint. While revenue fell 4% year over year, like‑for‑like sales excluding India were up 1%, supported by 2% volume growth and a sizable 5% foreign‑exchange tailwind that helped soften market weakness.

EBITDA and EPS Came In Well Ahead of Expectations

Profitability surprised to the upside versus management’s own forecasts. Adjusted Q1 EBITDA reached $72 million, a full $17 million above the top end of guidance, and adjusted loss per share of $0.23 was $0.15 better than the guidance midpoint, signaling tight cost control even as end‑markets remain under pressure.

New Active Ingredients Deliver Rapid Growth

FMC’s innovation engine showed real traction in the quarter. Sales of new active ingredients doubled compared with last year, and management expects further gains driven by launches and registrations for molecules such as fluindapyr and Dodhylex, positioning the portfolio for mix improvement over the medium term.

Isoflex EU Approval Marks a Strategic Breakthrough

The Isoflex herbicide secured approval in the European Union, the first new herbicide cleared there since 2019. FMC plans commercial launches beginning in 2027, targeting more than 55 million planted hectares, while exemption requests in Italy, Germany, France and Spain could add upside in the second half.

Rynaxypyr Brand Shows Resilience Post‑Patent

Despite patent expirations, FMC expects branded Rynaxypyr sales to hold around $600 million in 2026. Management cited early signs of volume growth, a shift toward higher‑load formulations and some share gains versus competing insecticide classes, suggesting the flagship franchise can remain a durable profit contributor.

Debt Reduction Plan Anchors Balance Sheet Strategy

Management outlined aggressive deleveraging goals, targeting about $1 billion of debt repayment in 2026. The plan relies on proceeds from the India divestiture, licensing arrangements and sales of noncore assets and real estate, with roughly $700 million already in advanced negotiations, giving investors some visibility.

Revolver Expansion and Planned Refinancing Boost Liquidity

FMC amended its revolving credit facility to a secured $2 billion line maturing in June 2028. The company now has direct liens on about $6 billion of collateral, potentially rising to $9 billion with guarantees, and intends to issue secured high‑yield debt to redeem $500 million of notes, subject to market conditions.

Price Erosion Highlights Competitive and Partner Pressures

Overall prices dropped about 6% in Q1 as partner diamide sales fell and branded Rynaxypyr was repositioned. Non‑diamide products saw low single‑digit price declines, and legacy core offerings faced intense competition in Latin America and Asia, underscoring structural pricing challenges across FMC’s portfolio.

Guidance Signals Steep Near‑Term Profit Squeeze

Q2 revenue guidance of $850–$900 million implies around a 17% year‑on‑year decline, mainly from lower diamide partner sales and the removal of India. The company expects Q2 adjusted EBITDA to fall roughly 32% and adjusted EPS to drop about 70%, highlighting how mix and pricing headwinds will squeeze margins.

Full‑Year 2026 Outlook Points to Earnings Pressure

FMC reiterated full‑year 2026 guidance but the numbers show substantial profit strain. Sales are forecast at $3.6–$3.8 billion, down about 5% at the midpoint, while adjusted EBITDA is seen falling roughly 17% and adjusted EPS about 41%, reflecting weaker partner business and tough competitive dynamics.

Leverage and Interest Costs Remain Elevated

Gross debt stands near $4.5 billion, with net debt around $4.1 billion and leverage at over five times trailing EBITDA. Q1 interest expense was $64.8 million, up $14.7 million year over year, and full‑year interest is expected between $255 million and $275 million, keeping financing costs a key drag on earnings.

Free Cash Flow Stays Under Strain

First‑quarter free cash flow was a negative $628 million, slightly worse than the prior year. For 2026, FMC guides to a wide band from negative $65 million to positive $65 million, breakeven at the midpoint, and this already factors in about $150 million of restructuring cash, leaving little margin for error.

Demand Softness from Customer Caution

Growers and distributors were described as cautious, facing margin pressure and liquidity stress. This has increased the use of generic products and willingness to skip preventative applications, creating a meaningful demand risk in the first half as farmers pull back on higher‑value crop protection purchases.

Cost Inflation and Tariff Recovery Uncertainties

Management highlighted rising energy, transport and petrochemical costs, partly linked to geopolitical tensions. Tariff recovery remains uncertain, and while FMC currently assumes a net offset, timing and magnitude are unclear, posing additional risk to already pressured operating margins.

Partner Diamide Sales Decline Weighs on Outlook

Sales of partner‑manufactured Rynaxypyr are expected to shrink sharply, falling from about $200 million to below $100 million in 2026. This drop is a major contributor to revenue and price headwinds, intensifying the need for FMC to grow its own branded and new‑active businesses.

Forward Guidance: Trough in H1, Gradual H2 Recovery

FMC’s guidance frames 2026 as a transition year, with H1 representing the earnings trough and a modest recovery expected in H2. Second‑half results are projected to be broadly in line with last year, while foreign exchange is seen neutral for the full year, and successful asset sales are critical to meeting debt‑reduction targets.

FMC’s earnings call offered a cautious but constructive roadmap for investors. Near‑term profits, cash flow and leverage are clear weak spots, and pricing remains under pressure. Yet innovation, regulatory wins and a focused deleveraging plan provide levers for recovery, making execution over the next 18–24 months the key driver for the stock.